Trial Profile
A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Oct 2023
Price :
$35
*
At a glance
- Drugs Nalbuphine (Primary)
- Indications Prurigo nodularis
- Focus Registrational; Therapeutic Use
- Acronyms PRISM
- Sponsors Trevi Therapeutics
- 13 Oct 2023 Results from this study was presented by Professor Elke Weisshaar on October 13th at the European Academy of Dermatology & Venereology (EADV) Congress 2023 in Berlin, Germany.
- 13 Oct 2023 The 52-week results presented in a Trevi Therapeutics media release.
- 04 Apr 2023 Status changed from active, no longer recruiting to completed.